Pharmacokinetic study of esomeprazole in patients with hepatic impairment

European Journal of Gastroenterology and Hepatology

Volumn 14, Issue 5, 2002, Pages 491-496

  Sjövall, Henrik ^a   Björnsson, Einar ^a   Holmberg, Johan ^a   Hasselgren, Göran ^a   Röhss, Kerstin ^a   Hassan Alin, Mohammed ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Esomeprazole; Gastro oesophageal reflux disease; Hepatic impairment; Pharmacokinetics; Proton pump inhibitors

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERANCE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; ISOMER; LIVER DISEASE; MALE; PRIORITY JOURNAL; STEADY STATE;

ADMINISTRATION, ORAL; ADULT; ANTI-ULCER AGENTS; CASE-CONTROL STUDIES; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OMEPRAZOLE;

EID: 0036094692     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200205000-00005     Document Type: Article

References (17)

1. Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-oesophageal reflux disease
2. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomised controlled trial
3. Esomeprazole is superior to omeprazole for the healing of erosive esophagitis (EE) in GERD patients
4. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: Focus on omeprazole, lansoprazole and pantoprazole
5. Cytochrome P450 and the metabolism of proton pump inhibitors: Emphasis on rabeprazole
6. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes
7. Pharmacokinetics (PK) and effect on pentagastrin-stimulated peak acid output (PAO) of omeprazole (O) and its two optical isomers, esomeprazole/S-omeprazole (E) and R-omeprazole (R-O)
8. Effects of liver disease on pharmacokinetics: An update
9. 14C] omeprazole in patients with liver cirrhosis
10. Pharmacokinetics of omeprazole in cirrhotic patients
11. Pharmacokinetics of lansoprazole after repeated administration in cirrhosis patients
12. Pharmakokinetic von pantoprazol bei patienten mit leberzirrhose
13. Pharmacokinetics of pantoprazole in patients with liver insufficiency due to chronic hepatitis
14. Rabeprazole: Pharmacokinetics in patients with stable, compensated cirrhosis
15. Transection of the oesophagus for bleeding oesophageal varices
16. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography
17. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects